These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 35275559)

  • 41. Synuclein-One study: skin biopsy detection of phosphorylated α-synuclein for diagnosis of synucleinopathies.
    Gibbons CH; Freeman R; Bellaire B; Adler CH; Moore D; Levine T
    Biomark Med; 2022 May; 16(7):499-509. PubMed ID: 35272481
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Associations Between APOE Variants, Tau and α-Synuclein.
    Rodriguez-Vieitez E; Nielsen HM
    Adv Exp Med Biol; 2019; 1184():177-186. PubMed ID: 32096038
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of cardiovascular autonomic failure in the differential diagnosis of α-synucleinopathies.
    Leys F; Wenning GK; Fanciulli A
    Neurol Sci; 2022 Jan; 43(1):187-198. PubMed ID: 34817726
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Spinal cord lesions in sporadic Parkinson's disease.
    Del Tredici K; Braak H
    Acta Neuropathol; 2012 Nov; 124(5):643-64. PubMed ID: 22926675
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cellular milieu imparts distinct pathological α-synuclein strains in α-synucleinopathies.
    Peng C; Gathagan RJ; Covell DJ; Medellin C; Stieber A; Robinson JL; Zhang B; Pitkin RM; Olufemi MF; Luk KC; Trojanowski JQ; Lee VM
    Nature; 2018 May; 557(7706):558-563. PubMed ID: 29743672
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CD8 T cell nigral infiltration precedes synucleinopathy in early stages of Parkinson's disease.
    Galiano-Landeira J; Torra A; Vila M; Bové J
    Brain; 2020 Dec; 143(12):3717-3733. PubMed ID: 33118032
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Upregulation of α-synuclein following immune activation: Possible trigger of Parkinson's disease.
    Kasen A; Houck C; Burmeister AR; Sha Q; Brundin L; Brundin P
    Neurobiol Dis; 2022 May; 166():105654. PubMed ID: 35143968
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.
    Mandler M; Valera E; Rockenstein E; Weninger H; Patrick C; Adame A; Santic R; Meindl S; Vigl B; Smrzka O; Schneeberger A; Mattner F; Masliah E
    Acta Neuropathol; 2014; 127(6):861-79. PubMed ID: 24525765
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lovastatin ameliorates alpha-synuclein accumulation and oxidation in transgenic mouse models of alpha-synucleinopathies.
    Koob AO; Ubhi K; Paulsson JF; Kelly J; Rockenstein E; Mante M; Adame A; Masliah E
    Exp Neurol; 2010 Feb; 221(2):267-74. PubMed ID: 19944097
    [TBL] [Abstract][Full Text] [Related]  

  • 50. TIGAR inclusion pathology is specific for Lewy body diseases.
    López KLR; Simpson JE; Watson LC; Mortiboys H; Hautbergue GM; Bandmann O; Highley JR
    Brain Res; 2019 Mar; 1706():218-223. PubMed ID: 30267647
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Formation and development of Lewy pathology: a critical update.
    Jellinger KA
    J Neurol; 2009 Aug; 256 Suppl 3():270-9. PubMed ID: 19711116
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neuropathological spectrum of synucleinopathies.
    Jellinger KA
    Mov Disord; 2003 Sep; 18 Suppl 6():S2-12. PubMed ID: 14502650
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicity.
    Price DL; Rockenstein E; Ubhi K; Phung V; MacLean-Lewis N; Askay D; Cartier A; Spencer B; Patrick C; Desplats P; Ellisman MH; Masliah E
    PLoS One; 2010 Nov; 5(11):e14020. PubMed ID: 21103359
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impaired Sphingolipid Hydrolase Activities in Dementia with Lewy Bodies and Multiple System Atrophy.
    Usenko TS; Senkevich KA; Bezrukova AI; Baydakova GV; Basharova KS; Zhuravlev AS; Gracheva EV; Kudrevatykh AV; Miliukhina IV; Krasakov IV; Khublarova LA; Fursova IV; Zakharov DV; Timofeeva AA; Irishina YA; Palchikova EI; Zalutskaya NM; Emelyanov AK; Zakharova EY; Pchelina SN
    Mol Neurobiol; 2022 Apr; 59(4):2277-2287. PubMed ID: 35066761
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Parkinson's disease and other alpha-synucleinopathies.
    Goedert M
    Clin Chem Lab Med; 2001 Apr; 39(4):308-12. PubMed ID: 11388653
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neuropathology underlying clinical variability in patients with synucleinopathies.
    Halliday GM; Holton JL; Revesz T; Dickson DW
    Acta Neuropathol; 2011 Aug; 122(2):187-204. PubMed ID: 21720849
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease.
    Del Tredici K; Hawkes CH; Ghebremedhin E; Braak H
    Acta Neuropathol; 2010 Jun; 119(6):703-13. PubMed ID: 20229352
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Progression of phosphorylated α-synuclein in Macaca fuscata.
    Kawakami I; Motoda A; Hashimoto M; Shimozawa A; Masuda-Suzukake M; Ohtani R; Takase M; Kumashiro M; Samejima K; Hasegawa M
    Brain Pathol; 2021 Sep; 31(5):e12952. PubMed ID: 33754430
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Alpha Synuclein: Neurodegeneration and Inflammation.
    Forloni G
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982988
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phosphorylated α-Synuclein Deposits in Cutaneous Nerves of Early Parkinsonism.
    Nolano M; Caporaso G; Manganelli F; Stancanelli A; Borreca I; Mozzillo S; Tozza S; Dubbioso R; Iodice R; Vitale F; Koay S; Vichayanrat E; da Silva FV; Santoro L; Iodice V; Provitera V
    J Parkinsons Dis; 2022; 12(8):2453-2468. PubMed ID: 36373295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.